Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$3.0 - $15.17 $340,020 - $1.72 Million
113,340 New
113,340 $553,000
Q3 2022

Nov 14, 2022

BUY
$13.96 - $19.67 $149,344 - $210,429
10,698 Added 10.42%
113,355 $1.63 Million
Q2 2022

Aug 15, 2022

SELL
$8.22 - $15.13 $12,149 - $22,362
-1,478 Reduced 1.42%
102,657 $1.55 Million
Q1 2022

May 11, 2022

BUY
$6.55 - $17.42 $5,174 - $13,761
790 Added 0.76%
104,135 $1.24 Million
Q4 2021

Feb 11, 2022

SELL
$15.51 - $29.31 $4,482 - $8,470
-289 Reduced 0.28%
103,345 $1.68 Million
Q3 2021

Nov 12, 2021

BUY
$27.47 - $37.31 $329,859 - $448,018
12,008 Added 13.11%
103,634 $2.96 Million
Q2 2021

Aug 11, 2021

SELL
$25.45 - $37.64 $236,277 - $349,449
-9,284 Reduced 9.2%
91,626 $3.1 Million
Q1 2021

May 13, 2021

SELL
$29.16 - $51.96 $199,716 - $355,874
-6,849 Reduced 6.36%
100,910 $3.05 Million
Q4 2020

Feb 09, 2021

BUY
$37.86 - $54.26 $100,329 - $143,789
2,650 Added 2.52%
107,759 $5.34 Million
Q3 2020

Nov 12, 2020

BUY
$35.13 - $43.62 $17,775 - $22,071
506 Added 0.48%
105,109 $4.04 Million
Q2 2020

Aug 12, 2020

BUY
$23.66 - $49.53 $452,852 - $948,004
19,140 Added 22.4%
104,603 $4.52 Million
Q1 2020

May 06, 2020

BUY
$14.39 - $35.8 $23,470 - $58,389
1,631 Added 1.95%
85,463 $2.23 Million
Q4 2019

Feb 14, 2020

BUY
$23.81 - $33.78 $591,226 - $838,791
24,831 Added 42.09%
83,832 $2.62 Million
Q3 2019

Nov 07, 2019

BUY
$21.57 - $31.37 $25,280 - $36,765
1,172 Added 2.03%
59,001 $1.54 Million
Q2 2019

Aug 12, 2019

BUY
$19.51 - $28.31 $733,751 - $1.06 Million
37,609 Added 186.0%
57,829 $1.32 Million
Q1 2019

May 14, 2019

BUY
$18.21 - $26.21 $368,206 - $529,966
20,220 New
20,220 $530,000

Others Institutions Holding YMAB

About Y-mAbs Therapeutics, Inc.


  • Ticker YMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,719,500
  • Market Cap $487M
  • Description
  • Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...
More about YMAB
Track This Portfolio

Track Bank Of New York Mellon Corp Portfolio

Follow Bank Of New York Mellon Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

News

Stay updated on Bank Of New York Mellon Corp with notifications on news.